Neurocrine Not Giving Up On Luvadaxistat Despite Phase II Miss

 
• By Joseph Haas
Schizophrenia
Despite disappointing data, Neurocrine thinks its schizophrenia drug could offer cognitive benefit

More from Clinical Trials

More from R&D